🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Stargardt Disease

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene NCT06435000n/a20 sites📍 San Diego📍 Aurora📍 Gainesville Splice Bio Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) NCT06445322n/a9 sites📍 San Francisco📍 Gainesville📍 Baltimore Ascidian Therapeutics, Inc · Tests: Prescreening Assessments A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) NCT06942572Phase 1, Phase 25 sites📍 Aurora📍 Miami📍 Boston Splice Bio · Tests: SB-007 Inherited Retinal Degenerative Disease Registry NCT02435940n/a1 site📍 Columbia Foundation Fighting Blindness A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) NCT07161544Phase 1, Phase 211 sites📍 Phoenix📍 Los Angeles📍 Los Angeles AAVantgarde Bio Srl · Tests: AAVB-039 The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration NCT06319872Phase 11 site📍 Rochester University of Rochester · Tests: Oral disulfiram Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease) NCT07002398Phase 1, Phase 21 site📍 Shanghai VeonGen Therapeutics GmbH · Tests: VG801 A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants NCT07836452Phase 11 site📍 Melbourne City Therapeutics · Tests: CITY-RBP4, Placebo A Study of DC6001 Tablet in Healthy Chinese Adult Subjects NCT07417566Phase 11 site📍 Beijing Heronova Pharmaceuticals · Tests: DC6001, Placebo Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration NCT06375239n/a1 site📍 Irvine Ray Therapeutics, Inc. A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults NCT07425574n/a15 sites📍 Phoenix📍 Palo Alto📍 Sacramento Astellas Pharma Global Development, Inc. · Tests: No Intervention Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene NCT01145196n/a1 site📍 Bethesda National Eye Institute (NEI) Stem Cell Ophthalmology Treatment Study II NCT03011541NA4 sites📍 Westport📍 Coral Springs📍 Vienna MD Stem Cells · Tests: Arm 1 Rod and Cone Mediated Function in Retinal Disease NCT02617966n/a1 site📍 Bethesda National Eye Institute (NEI) A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT NCT06805474n/a1 site📍 Dallas Nanoscope Therapeutics Inc. · Tests: Observational Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) NCT06467344Phase 1, Phase 211 sites📍 San Francisco📍 Gainesville📍 Miami Ascidian Therapeutics, Inc · Tests: ACDN-01 A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions NCT07734064Phase 14 sites📍 Phoenix📍 Southaven📍 Cincinnati Astellas Institute for Regenerative Medicine · Tests: ASP2020 Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease NCT07439887Phase 1, Phase 23 sites📍 Bakersfield📍 Pittsburgh📍 Bellaire Ray Therapeutics, Inc. · Tests: RTx-021 Study of ALK-001 on the Progression of Stargardt Disease NCT07419334Phase 314 sites📍 Phoenix📍 Aurora📍 Gainesville Alkeus Pharmaceuticals, Inc. · Tests: ALK-001, Placebo Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) NCT07502664n/a1 site📍 Irvine Ray Therapeutics, Inc. An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease NCT07063251EARLY Phase 11 site📍 Shanghai HuidaGene Therapeutics Co., Ltd. · Tests: HG005 Phase 1 Study of C.001 in Retinal Degeneration NCT07594236Phase 13 sites📍 Beverly Hills📍 Palo Alto📍 Sacramento Cellio Therapeutics Inc · Tests: Injection Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration NCT07266584NA1 site📍 Sydney Science Corporation · Tests: PRIMA Products
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy